Production (Stage)
Innate Pharma S.A.
IPHA
$2.08
-$0.09-4.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 3.04% | -1.91% | 0.85% | -168.86% | 1.09% |
| Total Depreciation and Amortization | -3.03% | -23.80% | -0.85% | -20.36% | -1.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.04% | 2,175.91% | -0.91% | -80.17% | -1.07% |
| Change in Net Operating Assets | -3.04% | -51.75% | -0.85% | 297.75% | 1.09% |
| Cash from Operations | 3.04% | -434.14% | -0.85% | 114.51% | 1.09% |
| Capital Expenditure | 3.03% | 61.00% | 0.85% | -579.65% | 1.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -1.10% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.04% | 604.11% | -0.85% | -94.10% | -1.09% |
| Cash from Investing | -3.04% | 806.06% | -0.85% | -95.50% | -1.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -2.17% | 0.00% | -476.27% | 0.00% |
| Issuance of Common Stock | 0.00% | 2,948.39% | 0.00% | 97.87% | 0.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3.04% | 60.32% | 0.85% | -505.96% | 1.07% |
| Foreign Exchange rate Adjustments | 3.01% | 1.45% | 0.86% | -301.01% | -1.14% |
| Miscellaneous Cash Flow Adjustments | 16.67% | -220.00% | 0.00% | -- | -- |
| Net Change in Cash | 3.04% | -496.86% | 0.84% | 23.35% | 1.09% |